Marwan Bukhari retweeted
Replying to @JRCPTB @gmcuk @RCPEdin @rcpsglasgow @RCPhysicians @RCP_RDC @RCPEdinTrainees @RCPSGResidents @NHSNSS
The first panel discussion of today explores ‘how do we better promote the quality of medical training?’. We are eager to hear from several panellists as well as questions posed from other delegates.
Marwan Bukhari retweeted
Still a chance to sign up to our last MorBLIME session of the year, coaching and mentoring excellence for education leaders.
Dec 5th York
mededleaders.co.uk/event/mor…
Marwan Bukhari retweeted
That was an amazing and inspirational day with the Doctors Training Team
#Balance
#Purpose
#Development
#DoctorsTraining
Marwan Bukhari retweeted
Happy #WorldASDay2024 to any #physiotherapists #rheumatology consultants/ doctors & patients who follow me. Check out resources from @NASSexercise nass.co.uk & @AStretch_Physio - more retweets to follow @BfwMsk @TherapiesRLI @NassLancaster @BlackpoolHosp @UHMBT
Happy #WorldASDay2024 from all of us from @AStretch_Physio to all our colleagues helping diagnose, treat & support and even more so our patients across the UK & the 🌍
Here is a top tip from the marvellous Mo Motion @MotionMop #axialSpA #ankylosingspondylitis #exercise
Marwan Bukhari retweeted
The team @DEMEC23 representing @MedEdLeaders and all enjoying the conference
#ValuingMedEd #TeamWorkMakestheDreamWork
Marwan Bukhari retweeted
We are delighted to be @DEMEC23 promoting our small grant call on the theme of #ValuingMedEd
In support of our 5th theme in our new best practice standards for valuing medical educators.
Come and get a leaflet or check out our website for more details.
Marwan Bukhari retweeted
We are delighted to be here at #DEMEC23 please come and visit us at our stand to discuss all things #ValuingMedEd and meet the team and our regional reps
Marwan Bukhari retweeted
Excellent work by @DrGabrielFP @AliDuarteMD and colleagues published in @RheumJnl on multi-morbidity in #SLE 👏🏻
📑 academic.oup.com/rheumatolog…
I know this will also be of interest to @gagan43 @ElenaNikiUK @Emanelfar77 too!
Marwan Bukhari retweeted
We're delighted to publish our first virtual roundtable! 👀 Watch our expert speakers discuss health inequalities in patients with rheumatic disease.
A big thanks to speakers @GenQ5Lesley, @ErnestChoy1 and @RJ_Hollick, and moderator @drdj 🤗
👉 bit.ly/3MdeElB
Marwan Bukhari retweeted
Rheumatology is recruiting! We're looking for new Associate Editors with expertise in osteoarthritis, and paediatric and adolescent rheumatology.
Come and join @drdj and the team @RheumJnl ✨
👇 bit.ly/3PMEWfn
Marwan Bukhari retweeted
👆🏼#VEXAS syndrome is believed to only affect individuals above the age of 50.
😮We describe an early-onset case in a 23 y/o 🙎🏽♂️ with relapsing polychondritis.
🗝️Test for UBA1 mutations🧬, regardless of age, in adults with a VEXAS clinical phenotype.
@ivette_pataki @RheumJnl
Marwan Bukhari retweeted
Our high impact article collection from Rheumatology and Rheumatology Advances in Practice is now available!🌟
Explore our most cited, downloaded, and discussed articles, open access until December!
👉bit.ly/3D1o3HW
Marwan Bukhari retweeted
Is it time to reconsider #glucocorticoids in #RheumatoidArthritis?
In a new Viewpoint 👀, Maarten Boers discusses:
⭐ GC efficacy in RA
⭐ Acceptable levels of harm
⭐ Current recommendations & their issues
⭐ GCs as bridge & prolonged therapy
academic.oup.com/rheumatolog…
Marwan Bukhari retweeted
203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://nitter.cf/t.co/zSxt0W9ZhB
Marwan Bukhari retweeted
NEW: @Adeorlahmi et al. use real-world data from the Midlands Ankylosing Spondylitis Collaboration to investigate the effectiveness and safety of secukinumab in AS 🔍
👉 Secukinumab demonstrates clear benefit in AS, especially in TNFi-naïve patients.
https://nitter.cf/t.co/jmnfXzjUtI
Marwan Bukhari retweeted
An interesting analysis of unpublished clinical trials for rheumatic diseases from @EBRheum & co.
"Nearly one in five RCTs in rheumatology remain unpublished two years after trial completion..." 👀
academic.oup.com/rheumatolog…
#AllTrials
Marwan Bukhari retweeted
NEW: Clark and Jawad present a case of sabre tibia in Paget’s disease.
A) Sabre-like convexity of the right leg
B) Cortical thickening, trabecular enlargement and bowing of the tibia
C) Increased activity in the proximal two thirds via SPECT CT 👇
https://nitter.cf/t.co/EjCU0g06RP
Marwan Bukhari retweeted
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - A Cross-sequential study based on COVAD surveys
By @CoVADStudy
Via @RheumJnl
Congratulations to all team 👏🏼🥳🎉
academic.oup.com/rheumatolog…
Marwan Bukhari retweeted
NEW: @KearsleyFleet et al. compare the effectiveness of etanercept originator versus etanercept biosimilar amongst biologic-naïve RA patients treated in routine clinical-practice in the UK.
Read now! ▶️ https://nitter.cf/t.co/71uPOlARmW
Marwan Bukhari retweeted
✨We’re thrilled to announce the winners of our Trainee Publishing Programme✨
A huge congratulations to Shivani Gor, @sharpcharlotte, Pallavi Shamdasani, Lauren Huckerby and @cristianasieiro! 🤩
Explore the winning papers 👇
https://nitter.cf/t.co/60tZTFAJyO





























